April 2008
Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p4
Trade Publication
The article announces that the human parthenogenetic stem cell lines of biotechnology company International Stem Cell Corp. (ISCO) will be used in studies aimed at creating specific cell types to treat human neural diseases in Germany. Albrecht Mueller of the University of Wuerzburg will head the project. It states that the use of ISCO's cells by the university is one of several such collaborations already in place involving the company's proprietary cells.


Related Articles

  • Pycnogenol's Latest Bragging Rights.  // Diabetes Health;Apr/May2007, Vol. 16 Issue 2, p55 

    The article discusses the role of Pycnogenol in slowing uptake of glucose after a meal, according to a study led by Doctor Petra Hogger at the University of Wurzburg in Germany and published in an issue of the "Journal of Diabetes Research and Clinical Practice." The study reveals that...

  • Stem-cell lines set for German research.  // Medical Device Daily;3/4/2008, Vol. 12 Issue 43, p8 

    The article reports on the use of International Stem Cell's (ISCO) human parthenogenetic stem cell lines in Germany in studies aimed at creating cell types to treat neural diseases. The study will be headed by Albrecht Mueller of the University of Wuerzburg. ISCO chief executive Kenneth Aldrich...

  • Intl Stem Cell's Research Scientists Successfully Completed the First Series of Preclinical Animal Trials of Neuronal Cells.  // Biomedical Market Newsletter;10/17/2011, Vol. 21, p878 

    The article reports on the completion of International Stem Cell Corp.'s preclinical animal trials of neuronal cells derived from human parthenogenetic stem cell line (hpSC). The study has found out that the neuronal cells were able to survive in mice brains without giving rise to tumors. The...

  • Impurity of stem cell graft by murine embryonic fibroblasts - implications for cell-based therapy of the central nervous system. Molcanyi, Marek; Mehrjardi, Narges Zare; Schäfer, Ute; Haj-Yasein, Nadia Nabil; Brockmann, Michael; Penner, Marina; Riess, Peter; Reinshagen, Clemens; Rieger, Bernhard; Hannes, Tobias; Hescheler, Jürgen; Bosche, Bert // Frontiers in Cellular Neuroscience;Sep2014, Vol. 8, p1 

    Stem cells have been demonstrated to possess a therapeutic potential in experimental models of various central nervous system disorders, including stroke. The types of implanted cells appear to play a crucial role. Previously, groups of the stem cell network NRW implemented a feeder-based cell...

  • Max von Laue. Means, Richard // Max von Laue;1/1/2006, p1 

    Background information on German physicist and crystallographer Max von Laue is presented. The author reviews how von Laue made one of the great scientific discoveries of the twentieth century the first scientist to demonstrate X-ray diffraction in crystals. For this work, he was awarded the...

  • International Stem Cell Gets Parthenogenetic Patent. Chambers, Heather // San Diego Business Journal;6/14/2010, Vol. 31 Issue 24, p6 

    The article reports on the potential of the International Stem Cell Corp. in Oceanside, California, to receive a patent related to the development of human parthenogenetic stem cells.

  • Biotech Firm Establishing An Operation in India. Hirsch, Lou // San Diego Business Journal;7/26/2010, Vol. 31 Issue 30, p9 

    The article reports on the establishment of an affiliate company by International Stem Cell Corp. which will be used for the manufacture of pharmaceutical products in San Diego, California.

  • Stem Cell Ruling Won't Harm Programs, Biotech Predicts. Hirsh, Lou // San Diego Business Journal;9/6/2010, Vol. 31 Issue 36, p6 

    The article announces that the recent court action federal funding of embryonic stem cell research of the International Stem Cell Corp. (ISCO) won't negatively impact the business's therapeutic programs tied to human stem cells.

  • Biotech Takes Steps to Form European Subsidiary. Hirsh, Lou // San Diego Business Journal;8/2/2010, Vol. 31 Issue 31, p6 

    The article reports on Oceanside, California-based International Stem Cell Corp.'s preliminary financial arrangements to create a European subsidiary to be called ISCO Europe.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics